PRESS RELEASE – March 21, 2021
Oss, The Netherlands, March 21, 2021 — Citryll today announced it has appointed Patrick Round as Chief Medical Officer. Patrick will provide leadership and direction to Clinical development strategy, Clinical Operations, Clinical Affairs, Clinical Sciences, Data Management/ Biometrics, and Drug Safety. Patrick will report to Helmuth van Es, CEO, and will serve on the Management Team.
Patrick Round graduated as a physician from Charing Cross Hospital Medical School in 1982. He has 30 years of experience in the pharmaceutical industry starting at Novo Nordisk and then Glaxo Wellcome. He has been Chief Medical Officer at Celltech, Cambridge Antibody Technology and Xention. Over the past 12 years he has taken the role of Chief Medical Officer at a number of biotech start-up companies across a wide range of therapeutic areas including companies Dezima and NorthSea Therapeutics.
“We warmly welcome Patrick and are pleased to have him join the Citryll team. His clinical vision and proven leadership, as well as his extensive clinical drug development experience, will strengthen our clinical development efforts and support the progress of Citryll’s development programs.”, said CEO and executive board member Helmuth van Es.
“Citryll is a leader and pioneer in the NETosis space with a first-in-class therapeutic antibody in development. I am excited to join the Citryll team and participate in development of a highly innovative asset and advance it into the clinic and beyond” said Patrick Round.
In June 2020 Citryll closed a series A fundraise of € 18,5 M/ $21 M in total with Seventure and Biogeneration Ventures as new investors and support of earlier investors BOM Brabant Ventures, Brightgene, ModiQuest, Curie capital as well as significant financial support from the Dutch Governement at RVO.nl. Citryll is developing its antagonist of NET formation and NETs for autoimmunity and inflammatory conditions where NET biology contributes to pathology and disease progression.
About Citryll B.V.
Citryll B.V. is a private pharmaceutical company based in Oss, the Netherlands at the Pivot
Park and is dedicated to the development and commercialization of therapeutics that target
NETosis and NETs. Citryll was founded in 2015 by ModiQuest B.V., originator of the tACPA
patents, Helmuth van Es, CEO Citryll, and Renato Chirivi of ModiQuest B.V., CSO Citryll
and co-inventor of tACPA.
Contact: Helmuth van Es at email@example.com, http://www.citryll.com/